Summit Therapeutics PLC (LSE:SUMM) - Overview

Stock Report

Summit Therapeutics PLC SUMM

Last Price
GBX173.50

Day Change
3.50|2.06%

As of 06/12/2016
10:07:39 GMT | GBX
Minimum 15 Minutes Delay.

Last Close170.00p
Day Range167.03 - 173.50
Mkt Cap105.10Mil
52-Wk Range82.66 - 262.00
Yield %0.00
ISINGB00BN40HZ01
Volume1,636
P/E-5.98
P/SInfinity
P/CF-5.98

Share Price

Total Returns 05/12/2016

 Chg (%)  
More ...
Summit Therapeutics PLC-8.11 
FTSE 100 TR GBP1.22
 
Financials
201420152016
More ...
Income Statement
Turnover1.380.000.00
Operating Profit-6.71-12.71-20.18
Net Profit-6.09-11.36-17.09
Reported EPS-29.80-29.00-29.00
Balance Sheet
Current Assets3.1015.1920.86
Non Current Assets3.544.204.22
Total Assets6.6319.4025.08
Current Liabilities1.873.773.21
Total Liabilities1.874.433.94
Total Equity4.7614.9721.13
Cash Flow
Operating Cash Flow-6.22-11.98-18.58
Net Change in Cash-1.359.244.92
Broker Forecasts
Year EndingPre-taxEPSEPSgP/EPEGDPSYld %
More ...
'Broker Forecasts' provides consensus figures based on several brokers' views
20172.828.68-19.59---
2018-4.93-5.96--28.50---

Company Profile

Summit Therapeutics PLC is a biopharmaceutical company focused on the discovery, development and commercialization of novel medicines for indications for which there are no existing or only inadequate therapies.
 

Sector

Drug Manufacturers - Specialty & Generic

Market Position

861 of 1864 Companies

Index

FTSE AIM All Share

Outlook

(08/09/2016) no outlook statement

Next Event 19/12/2016

Next Q3 announcement
Ratios
CompSecMkt
More ...
PER (E)-46.2313.5916.10
Div Yld (E)0.004.234.35
PEG (E)0.000.550.19
ROCE-113.61209.79-30.25
Op Mrgn0.00-15.64-33.57
EPS Grwth0.008.6822.86
Dividends
PreviousLatest
More ...
Record Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00

Broker Sentiment

Strong Buy0
Buy1
Hold0
Sell0
Strong Sell0
  • Strong Sell
  • Strong Buy
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
More ...
Disclaimer
Directors
More ...
ChairmanDr. Frank Armstrong
Chief Executive OfficerMr. Glyn Edwards
AJ Bell includes AJ Bell Holdings Limited and its wholly owned subsidiaries. AJ Bell Management Limited and AJ Bell Securities Limited are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at Trafford House, Chester Road, Manchester M32 0RS. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2016 Morningstar. All rights reserved.